Sanjay Nilapwar works as Senior Research Investigator at Incyte.
In 2013 Nilapwar started working for Spirogen, prior to its takeover by Medimmune, where he worked on development of site-specific and stochastic PBD based conjugation at research scale, stability and analytical assay development and was instrumental in setting up large scale ADC purification lab within Medimmune.
He started working on protein conjugates at Piramal Lifescience by conjugating a range of therapeutic drugs including cytotoxics and radiolabeled chelates to therapeutic mAbs for Targeted therapies.
Nilapwar has more than 12 years of experience in protein/conjugates purification development and has published 9 papers and written couple of book chapters. He regularly speaks at ADC conferences and chairs conference session.
Nilapwar has earned his Ph.D in Molecular Biology and Biophysics from UCL, London and M. Pharm in Pharmaceutical Chemistry from Mumbai University.